Longitudinal Evaluation of a Novel BChE PET Tracer as An Early In Vivo Biomarker in the Brain of a Mouse Model for Alzheimer Disease by Rejc, Luka et al.






2021; 11(13): 6542-6559. doi: 10.7150/thno.54589 
Research Paper 
Longitudinal evaluation of a novel BChE PET tracer as an 
early in vivo biomarker in the brain of a mouse model for 
Alzheimer disease 
Luka Rejc1, Vanessa Gómez-Vallejo2, Ana Joya2,3, Oscar Moreno2, Ander Egimendia2,4, Pilar Castellnou2, 
Xabier Ríos-Anglada2, Unai Cossío2, Zuriñe Baz2, Rossana Passannante2, Ignacio Tobalina-Larrea5,6, Pedro 
Ramos-Cabrer2,7, Albert Giralt8,9,10,11, Magdalena Sastre12, Estibaliz Capetillo-Zarate7,10,13, Urban Košak14, 
Damijan Knez14, Stanislav Gobec14, Mariel Marder15, Abraham Martin3,7, Jordi Llop2,16 
1. University of Ljubljana, Faculty of Chemistry and Chemical Technology, Večna pot 113, 1000 Ljubljana, Slovenia 
2. CIC biomaGUNE, Basque Research and Technology Alliance (BRTA), Paseo Miramon 182, 20014, San Sebastian, Spain. 
3. Laboratory of Neuroimaging and biomarkers of inflammation, Achucarro Basque Center for Neuroscience, Science Park UPV/EHU, 48940 Leioa, Spain 
4. Multiple Sclerosis Unit, Biodonostia Health Institute, Donostia-San Sebastián, Spain 
5. Department of Nuclear Medicine, University Hospital of Araba (HUA), 01009 Vitoria-Gasteiz, Spain. 
6. Department of Surgery Radiology and Physical Medicine, Faculty of Medicine, University of the Basque Country, UPV/EHU,01009 Vitoria-Gasteiz, Spain 
7. IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain 
8. Departament de Biomedicina, Facultat de Medicina i Ciències de la Salut, Institut de Neurociències. Barcelona, Spain.  
9. Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain.  
10. Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), 28031 Madrid, Spain.  
11. Production and Validation Center of Advanced Therapies (Creatio), Faculty of Medicine and Health Science, University of Barcelona, 08036 Barcelona, 
Spain.  
12. Department of Brain Sciences, Imperial College London, Hammersmith Hospital, Du Cane Road, London W12 0NN. 
13. Department of Neuroscience, Faculty of Medicine and Nursery, University of the Basque Country UPV/EHU and Achucarro Basque Center for 
Neuroscience, Barrio Sarriena S/N, 48940 Leioa, Spain. 
14. University of Ljubljana, Faculty of Pharmacy, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia. 
15. Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, and Instituto de Química y Fisicoquímica Biológicas, Facultad de 
Farmacia y Bioquímica, Universidad de Buenos Aires, Junín 956, C1113AAD Buenos Aires, Argentina 
16. Centro de Investigación Biomédica en Red – Enfermedades Respiratorias (CIBERES).  
 Corresponding authors: Luka Rejc: luka.rejc@fkkt.uni-lj.si; +38614798596; Jordi Llop: jllop@cicbiomagune.es; +34943005333 
© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). 
See http://ivyspring.com/terms for full terms and conditions. 
Received: 2020.10.16; Accepted: 2021.03.22; Published: 2021.04.26 
Abstract 
Purpose: The increase in butyrylcholinesterase (BChE) activity in the brain of Alzheimer disease (AD) 
patients and animal models of AD position this enzyme as a potential biomarker of the disease. However, 
the information on the ability of BChE to serve as AD biomarker is contradicting, also due to scarce 
longitudinal studies of BChE activity abundance. Here, we report 11C-labeling, in vivo stability, 
biodistribution, and longitudinal study on BChE abundance in the brains of control and 5xFAD (AD 
model) animals, using a potent BChE selective inhibitor, [11C]4, and positron emission tomography (PET) 
in combination with computerised tomography (CT). We correlate the results with in vivo amyloid beta 
(Aβ) deposition, longitudinally assessed by [18F]florbetaben-PET imaging. 
Methods: [11C]4 was radiolabelled through 11C-methylation. Metabolism studies were performed on 
blood and brain samples of female wild type (WT) mice. Biodistribution studies were performed in female 
WT mice using dynamic PET-CT imaging. Specific binding was demonstrated by ex vivo and in vivo PET 
imaging blocking studies in female WT and 5xFAD mice at the age of 7 months. Longitudinal PET imaging 
of BChE was conducted in female 5xFAD mice at 4, 6, 8, 10 and 12 months of age and compared to 
age-matched control animals. Additionally, Aβ plaque distribution was assessed in the same mice using 
[18F]florbetaben at the ages of 2, 5, 7 and 11 months. The results were validated by ex vivo staining of BChE 
at 4, 8, and 12 months and Aβ at 12 months on brain samples. 
Results: [11C]4 was produced in sufficient radiochemical yield and molar activity for the use in PET 









cross the blood brain barrier (BBB) and rapid washout from the brain. Blocking studies confirmed 
specificity of the binding. Longitudinal PET studies showed increased levels of BChE in the cerebral 
cortex, hippocampus, striatum, thalamus, cerebellum and brain stem in aged AD mice compared to WT 
littermates. [18F]Florbetaben-PET imaging showed similar trend of Aβ plaques accumulation in the 
cerebral cortex and the hippocampus of AD animals as the one observed for BChE at ages 4 to 8 months. 
Contrarily to the results obtained by ex vivo staining, lower abundance of BChE was observed in vivo at 10 
and 12 months than at 8 months of age.  
Conclusions: The BChE inhibitor [11C]4 crosses the BBB and is quickly washed out of the brain of WT 
mice. Comparison between AD and WT mice shows accumulation of the radiotracer in the AD-affected 
areas of the brain over time during the early disease progression. The results correspond well with Aβ 
accumulation, suggesting that BChE is a promising early biomarker for incipient AD. 
Key words: Butyrylcholinesterase, PET, Positron Emission Tomography, Alzheimer Disease, Amyloid Beta. 
Introduction 
Alzheimer Disease (AD) is the most common 
cause of dementia. It is one of the major causes of 
death globally and the second cause of death among 
the population over 70, affecting 13 million 
worldwide, the number expected to increase to more 
than 100 million by 2050 [1]. Currently, there is no 
effective treatment for AD available on the market, 
nor is there any reliable option for the early diagnosis 
of the disease. The diagnosis is therefore mainly based 
on clinical symptoms, which occur at later stages of 
the disease, when it is much too late for successful 
medical intervention [2]. To overcome this growing 
problem and provide AD patients with better 
treatment options, there is an urgent need to identify 
new disease biomarkers to (i) enable longitudinal and 
non-invasive monitoring of disease progression, (ii) 
enable a targeted approach to design new treatment, 
diagnostic and theragnostic strategies by shedding 
light on the pathophysiology of AD and the 
mechanisms involved in disease progression, and (iii) 
provide with new tools for treatment response 
evaluation. 
It has been described that neuronal loss 
contributes to cognitive and behavioural symptoms of 
AD [3, 4]. Pathophysiologically, AD is characterized 
by the accumulation of amyloid-β (Aβ) aggregates in 
various conformations [5], the appearance of 
filamentous intraneuronal inclusions, dystrophic 
neurites and neurophilic threads whose main 
constituent is hyperphosphorylated Tau protein 
(p-Tau) [6], and synaptic dysfunction [7]. AD patients 
also exhibit neuroinflammation [8], structural 
cerebrovascular alterations and early deficits in 
cerebral glucose uptake and cerebral blood flow 
responses [9]. Some of these processes begin decades 
before the onset of clinical symptoms, constituting a 
unique opportunity for the early diagnosis of the 
disease and eventual evaluation of the response to 
treatment [10]. In fact, the most recent trends propose 
establishing a definition of AD based on the 
assessment of different biomarkers, and not on 
clinical symptoms [2]. The AT(N) scheme, recently 
published by the National Institute on Aging and 
Alzheimer’s Association [2], proposes three groups of 
biomarkers, based on the nature of the pathological 
processes they measure: Aβ plaque (A), fibrillary tau 
(T) and neurodegeneration or neuronal damage (N) 
biomarkers. The AT(N) biomarkers can be 
investigated non-invasively in vivo by the means of 
positron emission tomography (PET) imaging, using 
radiotracers to detect Aβ and p-Tau [11, 12]. This 
narrative shows how important the development of 
imaging tools based on different pathophysiological 
changes is; hence, out of the box search for new 
AD-specific biomarkers that would complement the 
existing diagnostic strategies is advantageous in order 
to obtain a reliable diagnostic method. 
In addition to the changes above described, 
decreased enzymatic activity of acetylcholinesterase 
(AChE) and increased enzymatic activity of 
butyrylcholinesterase (BChE) was observed by 
biochemical analysis of tissue homogenates in brain 
regions where levels of Aβ and pTau deposits are 
usually increased [13]. It seems that BChE takes over 
the role of AChE as the main enzyme for acetylcholine 
(ACh) deactivation [14, 15]. This theory is confirmed 
by recent studies that show recovery of mice cognitive 
functions after scopolamine-induced short-term 
memory loss, by treatment with BChE inhibitors [16, 
17]. Furthermore, knock-out of BChE in the 5xFAD 
mouse model of AD showed a reduction of fibrillar 
Aβ plaque deposition [18, 19]. These findings present 
a base for development of new imaging probes for the 
early or differential diagnosis of the disease, based on 
assessment of BChE levels in the brain.  
First attempts to determine BChE abundance 
based on its enzymatic activity in the brains of AD 
patients by in vivo PET imaging resulted in moderate 
success [20]. Contrary to prediction, BChE enzymatic 
activity decreased to 82 ± 14% in diseased individuals, 





suggesting that incremental BChE expression does not 
significantly contribute to ACh hydrolysis in AD, and 
that BChE was not a suitable target to distinguish AD 
from normal brain. The main reasons behind these 
negative results remain unclear, although unspecific 
binding, short ligand-enzyme latencies or migration 
of labelled metabolites after enzymatic hydrolysis of 
the radiotracer may play a role. Additionally, BChE 
was observed to interact with Aβ, which could affect 
its enzymatic function [21]. This could also explain 
low success of radiolabelled BChE substrates to 
visualize increase in levels of BChE in the reported 
study [20]. Recently, N-methylpiperidin-4-yl 
4-[123I]iodobenzoate, a radiotracer labelled with the 
gamma emitter iodine-123 and suitable to conduct 
single photon emission computed tomography 
(SPECT) imaging studies, was validated by 
autoradiography [22] and in vivo imaging [23]. The 
tracer proved efficient in quantifying cerebral BChE 
enzymatic activity and distinguished AD from 
healthy, age-matched mouse brains, showing 1.5- and 
2.0-fold differences (AD vs. wild type, WT) at 60 min 
post injection for the hippocampus and cerebral 
cortex, respectively, at the age of 11.1 ± 1.1 months. 
However, clinical SPECT has certain limitations with 
respect to PET, including lower sensitivity and 
spatiotemporal resolution [24]. Noteworthy, no 
information on how BChE levels change with age was 
obtained from this study, disabling the evaluation of 
BChE as AD progression biomarker. Although other 
attempts to develop PET-suitable radiotracers have 
been made, to the best of our knowledge there has 
been no reports on successful high resolution 
assessment of BChE biodistribution in vivo [25].  
In this work, we shed a light on new possibilities 
of using BChE as AD biomarker and discus pitfalls of 
detection and evaluation of this enzyme in vivo and ex 
vivo in a transgenic mouse model. With this purpose, 
we have radiolabelled a recently reported potent 
BChE inhibitor [16] with the positron emitter 
carbon-11 (11C), and validated its use as in vivo PET 
tracer in two stages. First, biodistribution, metabolism 
and blood-brain barrier (BBB)-crossing capacity was 
assessed in WT mice. In parallel, its capability to 
detect BChE levels in an AD mouse model was 
evaluated by ex vivo and in vivo PET-CT blocking 
studies, using mice with fully developed disease. 
Second, the potential of this radiotracer for the in vivo 
longitudinal investigation of BChE expression was 
evaluated using PET-CT in a mouse model of AD. The 
results were compared to Aβ deposition in the same 
mice, investigated using the validated radiotracer 
[18F]florbetaben [26, 27], to better evaluate the 
correlation of BChE with AD progression. Finally, the 
presence of both, BChE and Aβ, was confirmed by ex 
vivo tissue staining and/or immunohistochemistry 
(IHC). 
Materials and Methods 
General aspects and study design 
Animal handling was conducted in accordance 
with the European Council Directive 2010/63/UE. All 
experimental procedures were approved by the 
Ethical Committee at CIC biomaGUNE and local 
authorities (authorization number: PRO-AE-SS-095).  
For metabolism and biodistribution studies, 
female WT C57BL/6 mice (n = 6; age = 10 weeks at 
arrival; 12–14 weeks at use) were obtained from 
Charles River. For BChE ex vivo and in vivo blocking 
studies, female WT (C57BL/6) and 5xFAD 
(C57BL/6J-Tg(APPSwFlLon,PSEN1*M146L*L286V)67
99Vas/Mmjax, n = 2) mice were bred and housed in 
the animal facility of the Faculty of Psychology at the 
University of Barcelona and transferred to CIC 
biomaGUNE at the age of 7 months. Mouse 
genotyping was performed by polymerase chain 
reaction (PCR) in ear biopsy samples as described 
elsewhere [28]. For longitudinal imaging studies, 
female WT C57BL/6J × SJL/J F1 mice (n = 10; control 
group), and female transgenic hemizygous 5xFAD 
(B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799V
as/Mmjax) mice (n = 13; study group) were obtained 
from The Jackson Laboratory (Bar Harbor, ME, USA). 
Animals arrived to CIC biomaGUNE at the age of 8–
10 weeks and were imaged at different time points 
(see below). Imaging was performed during light 
phase of the light–dark cycle. Six additional animals 
per group were sacrificed at the ages of 4 (n = 2 per 
group), 8 (n = 2 per group) and 12 (n = 2 per group) 
months of age and the brains harvested for ex vivo 
studies.  
Chemistry and radiochemistry 
The synthesis of [18F]florbetaben was performed 
using a TRACERlab FXFN synthesis module (GE 
Healthcare) by 18F-fluorination of the N-BOC- 
protected precursor followed by hydrolysis, as 
previously described [29] (see ESI for details). The 
synthesis of the 11C-labelled BChE inhibitor (±)[11C]N- 
((1-Benzylpiperidin-3-yl)methyl)-N-(2-methoxyethyl)
naphthalene-2-sulfonamide ([11C]4) (Scheme 1B) was 
achieved by 11C-methylation of (±)N-[(1-benzyl-
piperidin-3-yl)methyl]-N-(2-hydroxyethyl)naphthale
ne-2-sulfonamide 3 (prepared according to Scheme 
1A; see ESI for experimental details). The 
hydrochloride salt of (±)N-((1-benzylpiperidin- 
3-yl)methyl)-N-(2-methoxyethyl)naphthalene-2-sulfo
namide (4) was prepared as previously described [16]. 






Scheme 1. A) Reaction for the preparation of (±)N-[(1-benzylpiperidin-3-yl)methyl]-N-(2-hydroxyethyl)naphthalene-2-sulfonamide (3). Reagents and conditions: (i) see ref. [16]; 
(ii) 2-bromoethane-1-ol, K2CO3, dry DMF, room temperature to 100 °C, 18 h, under argon; B) radiosynthesis of [11C]4 by 11C-methylation of the precursor 3. 
 
Metabolite analysis 
For metabolite analysis, mice (n = 4) were 
injected intravenously (tail vein) with [11C]4 under a 
general anaesthesia (5% isoflurane in pure O2 for 
induction; 1–2% isoflurane in pure O2 for 
maintenance; flow = 1 L/min). At pre-determined 
time points (5 and 15 min, n = 2 per time point) blood 
samples (ca. 200 µL) were obtained by cardiac 
puncture and animals were immediately perfused 
with physiologic saline solution. After complete 
perfusion, the brain was harvested. Blood samples 
were processed to separate the plasma, which was 
diluted with an equal volume of acetonitrile and 
centrifuged. The brain was homogenized in a glass 
homogenizer tube and acetonitrile in ultrapure water 
(1:1; 500 µL) was added. The supernatant from the 
blood plasma and the brain homogenates were 
analysed by HPLC (see ESI). The total sample process 
time after sacrifice was 10 min for blood plasma and 
30 min for brain homogenates. 
PET-CT biodistribution studies 
Whole body imaging studies (n = 2) to 
investigate biodistribution were conducted using PET 
in combination with computerized tomography (CT), 
using the β- and X-cube micro systems (Molecubes, 
Gent, Belgium). Anaesthesia was induced with 3.0–
5.0% isoflurane in pure oxygen and maintained 
during imaging studies with 1.5–2.0% isoflurane in 
pure oxygen. PET scan started 30 ± 5 s after 
intravenous administration (tail vein) of 10% EtOH in 
saline solution containing [11C]4 (5.1 ± 0.8 MBq; 0.029 
± 0.004 nmol; see Table S1, animals 28 and 29), to 
allow for animal assembly to PET bed and the scan 
initialization. Dynamic whole-body images were 
acquired list-mode in one bed position in a 511 keV ± 
30% energetic window, with a total acquisition time of 
90 min. The scan times were corrected for the delay in 
the PET experiment initialization. A CT scan was 
acquired immediately after finalisation of the PET 
imaging session. PET images were reconstructed with 
OSEM-3D iterative algorithm, using the following 
frames: 4 × 10 s, 4 × 30 s, 4 × 60 s, 4 × 120 s, 4 × 240 s, 3 
× 900 s, 1 × 860 s. Images were analysed using π-MOD 
image analysis software (π-MOD Technologies Ltd, 
Zurich, Switzerland). Volumes of interest (VOIs) were 
manually drawn in major organs, namely brain, 
lungs, kidneys, liver, bladder and heart, using the CT 
images for anatomical reference, and decay–corrected 
time–activity curves were obtained. 
PET-CT blocking studies  
BChE blocking PET-CT imaging studies were 
conducted to evaluate the specificity of compound 4 
for the desired target, using β- and X-cube micro 
systems (Molecubes, Gent, Belgium). Anaesthesia was 
induced with 3.0–5.0 % isoflurane in pure oxygen and 
maintained during imaging studies with 1.5–2.0 % 
isoflurane in pure oxygen. Baseline PET scans started 
30 ± 5 s after intravenous administration of 10% EtOH 
in saline solution containing [11C]4 (see Table S1 for 
administered doses; animals 24-27). Blocking PET 
scans were acquired the following day on the same 
animals, by co-administering [11C]4 (see Table S1) 
with hydrochloride salt of 4 (10 mg/kg; ca. 400 nmol 
per animal). In all cases, dynamic PET images were 
acquired in one bed position, with the brain centred in 





the middle of the field of view (FOV). The scan times 
were corrected for the delay in the PET experiment 
initialization. CT scans were acquired immediately 
after each PET acquisition. PET images were 
reconstructed with OSEM-3D iterative algorithm, 
using the following frames: 5 × 5 s, 5 × 10 s, 5 × 30 s, 5 
× 60 s, 4 × 120, 4 × 240 s, 4 × 400 s. Images were 
analysed using π-MOD image analysis software. 
Volumes of interest were delineated in different brain 
regions (cerebral cortex, hippocampus, striatum, 
cerebellum, brain stem and thalamus) using the M. 
Mirrione-T2 MRI template. Uptake in the different 
regions was determined as standardized uptake 
values (SUV), and relative increase for each animal 
(non-blocked vs. blocked) was determined and 
expressed in percentage.  
PET-CT longitudinal brain studies  
Longitudinal brain studies were performed 
using an eXplore Vista-CT small animal PET-CT 
system (GE Healthcare, WI, USA). The same WT and 
5xFAD mice were used to study longitudinal 
accumulation of [11C]4 and [18F]florbetaben in the 
brain. In all cases, anaesthesia was induced as 
described for biodistribution studies. Transgenic (AD) 
and age-matched control (WT) mice of the same 
genetic background were injected intravenously with 
[11C]4 (8.5 ± 3.4 MBq; range: 1.4–16.1 MBq; 0.012–0.130 
nmol; injected volume: 100–150 µL; 4, 6, 8, 10 and 12 
months of age; see Table S1 for detailed injection list, 
animals 1–23) or [18F]florbetaben (15 ± 8 MBq; injected 
volume: 100–150 µL; 2, 5, 7 and 11 months of age). In 
case of [11C]4, PET scan started 30 ± 5 s after 
administration of the radiotracer, to allow for animal 
assembly to PET bed and the scan initialization. The 
dynamic PET images (frames: 5 × 5 s, 5 × 10 s, 5 × 30 s, 
5 × 60 s, 4 × 120 s, 4 × 240 s, 4 × 400 s; total duration: 
59.4 min) were acquired in one bed position, with the 
brain centred in the middle of the field of view (FOV). 
The scan times were corrected for the delay in the PET 
experiment initialization. In case of [18F]florbetaben, 
30-min static PET images were acquired 30 min post 
intravenous injection in one bed position. CT scans 
(X-Ray energy: 40 kV; intensity: 140 µA) were 
acquired immediately after each PET acquisition. PET 
images were reconstructed using filtered back 
projection (FBP) applying random, scatter, and 
attenuation corrections and using a ramp filter with a 
cut off frequency of 1 Hz. Longitudinal deposition of 
BChE and Aβ was assessed in different brain regions 
(cerebral cortex, hippocampus, striatum, cerebellum, 
brain stem and thalamus for BChE; cerebral cortex, 
hippocampus, brain stem and cerebellum for Aβ) 
using the M. Mirrione-T2 MRI template available at 
π-MOD software. In case of [11C]4, time activity 
curves were obtained for different regions and 
expressed as standardized uptake values (SUV) to 
correct for injected dose and animal weight effects on 
the results. In case of [18F]florbetaben, the 
concentration of activity was determined in each 
region of interest (cortex, hippocampus and brain 
stem) as SUV value relative to the cerebellum (SUVr).  
For the generation of [11C]4 images, individual 
SUV images for each group (AD and WT) and time 
point were averaged. Voxel-by-voxel ratios of SUV 
values obtained at t = 6, 8, 10 and 12 months of age, 
with respect to t = 4 months, were displayed in 
different brain regions. For [18F]florbetaben, 
voxel-by-voxel SUVr values were determined in all 
brain regions, taking the average SUV value in the 
cerebellum as a reference. Images for data 
representation were created by voxel-by-voxel 
subtraction of SUVr values in the images obtained at t 
= 2 months from those obtained at t = 5, 7 and 11 
months of age. 
Ex vivo studies 
Brain preparation 
Animals were anesthetized with isoflurane, 
transcardially perfused with saline (20 mL, 0.9% 
NaCl, 0.01% sodium heparin) and the brain was 
removed, fast-frozen at -80 °C and cut in 25 µm- (ex 
vivo PET) or 10 µm- (staining and 
immunohistochemistry) thick sections in a cryostat 
and mounted on glass slides. 
Blocking studies 
Brain slices (3 consecutive slices per repetition; 
Bregma values of ca. 1.2, -2.8 and -5.8) of 8 months old 
WT and AD animals (2 animals per strain and 
condition) were pre-incubated with PBS buffer (10 
mM, pH = 7.4) for 15 min. Subsequently, samples 
were incubated (30 min, 25 °C) with 0.5 nM [11C]4 
both in the absence and presence of compound 4 (200 
nM; autologous blocking) or ethopropazine (200 nM; 
BChE inhibitor with different chemical structure; 
heterologous blocking). After incubation, brain slices 
were rinsed twice with the same buffer and once with 
ultrapure water, dried at 50 °C and then measured 
using a β-cube micro system (Molecubes, Gent, 
Belgium). Images were reconstructed using OSEM-3D 
iterative algorithm, regions of interest (ROIs) were 
defined in the whole brain slices and the surface 
concentration of radioactivity for each slice was 
determined. The ratio in concentration of 
radioactivity (blocked/non-blocked) was determined 
for each group (WT and AD) and Bregma value, and 
expressed as percentage. 






Butyrylcholinesterase staining was performed 
using the Karnovsky-Roots method with 
modifications [30, 31]. All reagents used in this 
protocol were purchased from Merck Life Science 
(Madrid, Spain). The substrate used for visualization 
of BChE activity was S-butyrylthiocholine iodide, and 
AChE activity was inhibited by BW284c51 
(1,5-bis[4-allyl dimethylammonium phenyl]pentan- 
3-one dibromide) at a final concentration of 0.02 mM. 
In brief, tissue sections were rinsed in maleate buffer 
(0.1 M, pH 7.4) for 30 min and then incubated for 2 h 
in 0.1 M maleate buffer (pH 6.8) containing 0.5 mM 
sodium citrate, 0.47 mM cupric sulfate, 0.05 mM 
potassium ferricyanide, 0.8 mM S-butyrylthiocholine 
iodide and 0.02 mM BW284c51. All sections were then 
rinsed with gentle agitation for 30 min in dH2O and 
placed in 0.1% cobalt chloride in water for 10 min. 
After further rinsing in dH2O, 1 mL of filtered 
phosphate buffer containing 3,3’-diaminobenzidine 
tetrahydrochloride (DAB; 1.39 mM) was added to 
each slide. After 5 min in the DAB solution, 50 µL of 
0.15% H2O2 in dH2O was added per ml of DAB 
solution, and the reaction was carried out for 20 min. 
Sections were then washed in 0.01 M acetate buffer 
(pH 3.3), dried overnight and mounted with Eukitt 
mounting medium for histology. Images were 
acquired with the Pannoramic MIDI II automated 
digital slide scanner (3DHistech Ltd., Hungary). For 
BChE inhibition, the same procedure was followed, 
but 0.032 mM ethopropazine hydrochloride was 
added to the maleate buffer to inhibit BChE activity. 
Amyloid immunohistochemistry 
Amyloid plaques were visualized using 
immunohistochemistry for Aβ protein. Frozen 
sections were fixed with 4% paraformaldehyde for 15 
min and rinsed three times for 5 min using 0.1 M PBS. 
Mouse on Mouse (M.O.M.®) peroxidase 
immunodetection kit was used following 
manufacture instructions (Vector Laboratories, CA, 
USA). In brief, endogenous enzyme activity was 
blocked with 3% H2O2 in 0.1 M PBS for 10 min 
followed by 0.1 M PBS washes. Mouse IgG was 
blocked with M.O.M blocking reagent for 1 h and 4G8 
primary antibody (1:500) diluted in M.O.M diluent 
was incubated for 30 min. To obtain negative control 
images, the tissue slices were incubated with M.O.M 
diluent without primary antibody. VECSTAIN Elite 
ABC reagent was incubated for 5 min and sections 
were exposed for 6 min to peroxidase substrate 
solution (Vector Laboratories, CA, USA). After air 
dried, sections were mounted with PDX mountant for 
histology (Sigma, Mi, USA). Images were acquired 
with the Pannoramic MIDI II automated digital slide 
scanner (3DHistech Ltd., Hungary).  
Thioflavin staining 
Thioflavin S staining was used to visualize 
fibrillar amyloid. Frozen sections were fixed with 4% 
paraformaldehyde for 15 min and rinsed with 0.1 M 
PBS 5 min 3 times. Sections were then incubated with 
0.01% Thioflavin S in 70% ethanol, diluted 1:10 in 0.1 
M PBS, for 10 min, washed with 0.1 M PBS and 
mounted with Fluoromont-G® (SouthernBiothech, 
AL, USA). To obtain negative control images, the 
slices were incubated with 70% ethanol diluted 1:10 in 
0.1 M PBS without Thioflavin S. Images were acquired 
with the Pannoramic MIDI II automated digital slide 
scanner (3DHistech Ltd., Hungary).  
Statistical analysis 
PET results were analysed using two-way 
ANOVA. Differences between groups (5xFAD vs WT) 
at each time point and differences between time 
points within each group were determined using 
Sidak’s multiple comparisons test. Differences were 
concluded significant for P values < 0. 05: P < 0.05, *; P 
< 0.01, **, P < 0.001, ***; and P < 0.0001, ****. Statistical 
tests were performed in GraphPad Prism 7.03 
(GraphPad Software, CA, USA). 
Results 
Radiosynthesis and physico-chemical 
properties of [11C]4 
By using the previously described captive 
solvent method [32] and in the presence of a strong 
base, sodium hydride, the radiosynthesis of [11C]4 
worked efficiently at room temperature in 5 min 
reaction time. Non-decay corrected radiochemical 
yields and molar activity values of 8 ± 4% and 161 ± 24 
GBq/µmol, respectively, were obtained in overall 
synthesis time of 50 min. Radiochemical purity at 
injection time was >95% in all cases. Logarithm 
partition coefficient (logP) of [11C]4 was 1.39 ± 0.03 (n 
= 3), suggesting that the polarity of the molecule is in 
the appropriate range to penetrate the blood brain 
barrier (BBB). This is in line with previous results that 
show BBB permeation ability for the non-labeled 
compound 4 using LC-MS/MS [16]. 
Biodistribution and pharmacokinetics of [11C]4 
Dynamic whole-body PET imaging studies (see 
Figure 1A for representative images; Figure 1B for 
time activity curves - TACs) performed in WT mice 
confirmed the BBB penetration capacity and 
subsequent clearance of [11C]4, with values of 
%ID/cm3 peaking at around t = 40 s (%ID/cm3 = 3.7 ± 
0.1%) and slowly decreasing afterwards. 





Biodistribution data shows rapid clearance of 
radioactivity from the blood, as deduced from the fast 
decrease in activity concentration in the VOI drawn in 
the heart. TACs also show significant accumulation of 
radioactivity in the liver, and presence of radioactivity 
in the kidneys, which is paralleled by a progressive 
increase of radioactivity in the bladder, confirming 
elimination via hepatobiliary and urinary routes. 
Consistent with previously reported metabolite 
analysis [16], plasma analysis confirmed the presence 
of two radioactive polar metabolites with tR of 2.0 
(major metabolite) and 3.4 min (minor metabolite) 
under our chromatographic conditions (tR for parent 
compound: 9.8 min). Altogether, metabolites 
accounted for 58% and 77% of the radioactivity in 
blood at t = 5 and 15 min after intravenous 
administration, respectively. Importantly, the 
presence of radioactive metabolites in the brain was 
lower, with values of 28% and 49% at t = 5 and 15 min 
after administration, respectively. Of these values, the 
metabolite with tR = 2 min accounted for 90% of total 
metabolites. 
In vivo BChE blocking studies 
Significantly higher initial brain uptake of [11C]4 
was observed in animals injected with a solution 
containing hydrochloride salt of 4 in AD animals 
(Figure 2A). As indicated by biodistribution studies, 
the radiotracer rapidly cleared from the brain. 
Interestingly, the radiotracer levels at 50–60 min after 
injection were lower for BChE-blocked animals than 
in non-blocked animals (Figure 2A, inset), with a 
decrease in uptake of ca. 20% in brain sub-regions 
such as the cortex (21.7 ± 2.9%), striatum (16.7 ± 6.2%), 
cerebellum (16.8 ± 7.9%), brain stem (22.7 ± 17.0%), 
and thalamus (21.1 ± 4.2%) and slightly lower in the 
hippocampus (7.7 ± 9.2%; Figure 2C) at the last 
imaging time point. The lower uptake in animals 
treated with the mixture of hydrochloride salt of 4 and 
[11C]4 was clearly visible on PET images (Figure 2D). 
Noteworthy, the concentration of radioactivity in the 
brain of WT animals under blocking conditions at the 
end of the imaging session was equivalent to the 
value obtained under non-blocking conditions (Figure 
2B, inset), with differences in both experimental 
scenarios below 3%, irrespective of the brain 
sub-region (Figure 2C).  
Ex vivo BChE blocking studies 
The concentration of radiotracer after incubation 
with [11C]4 in the presence of either the hydrochloride 
salt of 4 or ethopropazine hydrochloride at a 
concentration of 200 nM was lower than the 
concentration of radioactivity under non-blocking 
conditions for AD animals, irrespective of the location 
within the brain. Blocked/non-blocked ratios of 93.0 ± 
1.0% and 92.2 ± 1.6% (Bregma = 1.2; compound 4 and 
ethopropazine, respectively); 90.0 ± 2.6% and 87.2 ± 
3.8% (Bregma = -2.8; compound 4 and ethopropazine, 
respectively); and 92.2 ± 0.8% and 88.9 ± 1.8% (Bregma 
= -5.8; compound 4 and ethopropazine, respectively) 
were obtained for AD animals (Figure S1). Contrarily, 
values close to 100% (meaning no-blocking effect) 
were obtained for WT animals: 99.7 ± 2.8 and 100.3 ± 
3.5 (Bregma = 1.2; compound 4 and ethopropazine, 
respectively); 98.1 ± 2.2 and 99.1 ± 3.1 (Bregma = -2.8; 
compound 4 and ethopropazine, respectively); and 
97.3 ± 0.7 and 98.4 ± 1.8 (Bregma = -5.8; compound 4 
and ethopropazine, respectively). These values 
suggest a ca. 10% of specific binding in AD animals. 
Longitudinal imaging studies 
Dynamic PET-[11C]4 imaging showed evident 
differences between AD and control mice. Initially, at 
age of 4 months, dynamic curves for AD and WT 
animals at the whole brain level were almost 
equivalent (Figure S2); however, later time points (6 
and 8 months) reveal clear increase in the radiotracer 
uptake in AD compared to control mice (Figure S2). 
For easier comparison of the differences and to obtain 
regional information, time-activity curves were 
obtained for each brain region (CTX, HIP, STR, CB, 
THA, BS) and the last three time-frames (40–60 min 
after injection) of each scan were averaged and 
compared at different ages (Figure 3A). No significant 
difference in SUV and low intra-subject variability 
was observed between control and AD mice at the age 
of 4 months. Contrarily, the values in the cortex were 
significantly higher for AD animals than for 
aged-matched controls at 6 and 8 months of age (P 
values of 0.026 and 0.0098 for 6 and 8 months, 
respectively). Similar results were observed in other 
brain sub-regions e.g. striatum (P values of 0.049 and 
0.0063 for 6 and 8 months, respectively), cerebellum (P 
values of 0.0193 and 0.0102 for 6 and 8 months, 
respectively), thalamus (P values of 0.0159 and 0.0102 
for 6 and 8 months, respectively) and brain stem (P 
values of 0.049 and 0.0033 for 6 and 8 months, 
respectively) (Figure 3). For the hippocampus, 
significant differences with respect to control group 
were only observed at the age of 8 months (P = 
0.0047). Interestingly, no significant differences were 
observed at the age of 10 and 12 months in any of the 
brain sub-regions. The observed trend is more evident 
when comparing the standardized differences in the 
radiotracer uptake between AD and WT mice 
[(SUVAD – SUVWT)/SUVWT] (Figure 3B). Increase in 
relative uptake is in the range 0.30–0.43 at the age of 6 
months and 0.40–0.48 at the age of 8 months.  






Figure 1. A) PET images (maximum intensity projections, coronal views) obtained at different time points after intravenous administration of [11C]4 in WT female mice. PET 
images have been co-registered with CT images (representative slices) of the same animal for proper localization of the radioactive signal; B) time activity curves in the lungs, 
bladder, kidneys, liver, heart and brain after intravenous administration of [11C]4 in WT female mice. The results are expressed and mean ± SD, n = 2. 
 
The differences between time points and animal 
groups are clearly visible in PET images when 
dividing average, voxel-by-voxel, radiotracer uptake 
at 6, 8, 10, and 12 months of age by 4 months of age in 
all the animals of each group (Figure 4). All brain 
regions considered in the study clearly show 
increased uptake at the ages of 6 and 8 months with 
respect to 4 months, while quasi-equivalent values in 
both WT and AD animals are obtained at 10 and 12 
months of age.  
Uptake values of [18F]florbetaben in different 
brain regions were calculated relative to the 
cerebellum, which was taken as the reference region, 
as no Aβ pathology has been reported in this brain 
region in 5xFAD animals [33]. In the cortex, SUVr 
increased for AD animals from 2 to 5 months of age (P 
< 0.0001) to stabilize afterwards (Figure 5A). 
Progressive increase in SUVr values for AD animals 
over time was even more apparent in the 
hippocampus (Figure 5B). In WT animals, stable 
values over time were observed in both brain regions. 
When comparing values obtained for AD and 
age-matched WT animals, significant differences were 
observed at all ages in the cortex, with P values of 
0.0004, <0.0001 and <0.0001 for 5, 7 and 11 months, 
respectively (see Table S2 for more detailed 
information). In the hippocampus, the differences 
were even more significant, with P values <0.0001 at 
all times. Such differences can also be observed on the 
images, obtained by calculating, voxel-by-voxel, the 
difference between the brain images at 5, 7, and 11 
months of age and the image of the same animal at 
age of 2 months (Figure 5D). Contrarily, in the brain 
stem, a clear trend in uptake values vs. age could not 
be identified and differences with respect to the 
control group were not significant at any age (Figure 
5C). 






Figure 2. A, B) Time activity curves in the whole brain after intravenous administration of [11C]4 in AD (A) and WT (B) female mice. For blocking experiments (“blocked” in the 
figure) the radiotracer was co-injected with hydrochloride salt of compound 4 at a final dose of 10 mg/kg (injected amount of ca. 400 nmol per animal). For easier visualization 
of the uptake differences at the end of the blocking study, magnified graph of the last three time-points of PET imaging protocol (depicted by red square) is inset in A and B. Results 
are expressed as mean ± SD, n = 2; C) Percentage of blocking by co-administration of hydrochloride salt of 4 (dose = 10 mg/kg) in the whole brain (WB, considered as the sum 
of all brain regions segmented in the T2 Mirrione brain template provided by π-MOD software), cortex (CTX), striatum (STR), cerebellum (CB), hippocampus (HIP), brain stem 
(BS) and thalamus (THA), for both AD (grey bars) and WT (white bars) mice. Results are expressed as mean ± SD, n = 2; D) PET images (top: axial sections; bottom: coronal 
sections) obtained after administration of [11C]4 to AD mice under non-blocking (left) and blocking (right) conditions. Images correspond to the last time frame of the acquisition. 
Brain sub-regions are delineated for anatomical localization of the radioactive signal. 
 






Figure 3. A) Box plot diagrams of SUV in different brain regions (whole brain: WB, considered as the sum of all brain regions segmented in the T2 Mirrione brain template 
provided by π-MOD software; cortex: CTX; hippocampus: HIP; striatum: STR; cerebellum: CB; thalamus: THA; and brain stem: BS) after intravenous administration of [11C]4 to 
AD and WT animals at the ages of 4, 6, 8, 10 and 12 months. For the calculation of SUV values, the last three frames of time activity curves for each region have been averaged; 
probability values (difference AD vs. WT) are depicted as * (P < 0.05), ** (P < 0.01); B) relative increased uptake of [11C]4 in different brain regions of AD animals with respect 
to WT age-matched animals, calculated as (SUVAD – SUVWT)/SUVWT; yellow and green lines show increased uptake at the whole brain (WB) level at the ages of 6 and 8 months, 
respectively. Probability values (differences with respect to value at age = 4 months) are depicted as * (P < 0.05), ** (P < 0.01), *** (P < 0.001), and **** (P < 0.0001). 
 
Evaluation of BChE and Amyloid plaque 
staining 
Increased BChE enzymatic activity was observed 
in 5xFAD mice at the ages of 8 and 12 months with 
respect to 4 months in brain sub-regions investigated 
ex vivo, including the cerebral cortex (Figure 6), 
hippocampus (Figure 7A-F) and cerebellum (Figure 7 
G-I). The white matter displayed high enzymatic 
activity of BChE, as shown by the corpus callosum, in 
both 5xFAD and WT mice. The BChE staining was 
completely diminished by the use of the BChE 





inhibitor ethopropazine in 12m-WT and partially 
inhibited in 5xFAD mice (Figure S3). We speculate 
that the use of low concentration of ethopropazine for 
inhibition (0.032 mM compared to 0.06 mM), used in 
other similar studies that inhibited BChE to visualize 
the AChE activity [30] or an obstruction of BChE 
binding site when bound to plaques could be a culprit 
for these results. Additional experiments will be 
conducted to validate these claims.  
 
 
Figure 4. PET images (representative axial slices) obtained in AD and WT animals after intravenous administration of [11C]4 at different ages. Images have been generated by 
dividing, voxel-by-voxel, averaged images obtained at 6, 8, 10, and 12 months of age by averaged images obtained at 4 months of age. VOIs corresponding to the cortex, 
hippocampus, striatum, brain stem, thalamus and cerebellum are drawn for anatomical reference. 
 
Figure 5. A–C) Box plot diagrams representing uptake of [18F]florbetaben in the cortex (CTX; A), the hippocampus (HIP; B) and the brain stem (BS; C) for WT and AD animals 
at different ages, expressed as Standard Uptake Values relative to the cerebellum (SUVr); dots represent individual values; probability values are depicted as * (P < 0.05), ** (P < 
0.01), *** (P < 0.001), and **** (P < 0.0001); D) representative axial PET images corresponding to WT and AD animals at ages = 5, 7 and 11 months, representing, voxel-by-voxel, 
increased SUVr values with respect to the value at the age of 2 months for the same animal. PET images have been co-registered with a mouse brain atlas. Volumes of interest 
drawn in the cortex (red) and the hippocampus (orange) are displayed on each image. 






Figure 6. Staining for BChE enzymatic activity in 4, 8 and 12-month-old brains of WT 
(A, C and E) and 5xFAD mice (B, D and F) using the Karnovsky-Roots method. BChE 
staining showed increase of enzyme activity in the cerebral cortex of 5xFAD at 
different ages in comparison to WT (A to F) mice. Magnified images show the 
co-occurence of plaques with BChE enzyme activity in different regions of the 
cerebral cortex (B, D and F). 
 
 
Qualitative comparison between BChE and Aβ 
abundance in brain slices of 12-month old 5xFAD 
mice suggest that the area covered by plaques, 
abundant with BChE, was smaller than that observed 
by Thioflavin S or 4G8 immunostaining. Though, 
general distribution of BChE corresponded well to the 
distribution of Aβ deposits, suggesting coexistence of 
the two biomarkers.  
Discussion 
Compound 4 is a potent and selective BChE 
inhibitor, successfully used for restoration of 
cognitive abilities in vivo in mice. Previous studies 
demonstrated that compound 4 exhibits nanomolar 
affinity towards the active sites of BChE enzyme (Ki = 
1.29 and 2.01 nM for – and + enantiomer, respectively) 
and that it works as an inhibitor of the enzyme 
activity (IC50 = 4.91 and 15.3 nM for – and + 
enantiomer, respectively) [16]. Furthermore, 
compound 4 successfully helped mice recover from 
scopolamine-induced memory loss, indicating its 
function in vivo, probably through the inhibition of 
BChE [16]. To obtain a broad profile of off-target 
activity for the compound 4 in CNS, in vitro safety 
pharmacology profiling (SafetyScreen44™ Panel) was 
conducted by Eurofins Discovery Poitiers, France, at 
10 µM concentration of 4 (see full report for detailed 
experimental procedures and results in ESI-Annex). 
At this concentration, the compound showed no 
significant inhibition ability of dopamine (except for 
D2S receptor; 55.6% inhibition, a value very close to 
the cut-off limit, set at 50%), cannabinoid, nicotinic, or 
opioid receptors (with the exception of µ-opioid 
receptor; 82.7% inhibition). The later, in a separate 
experiment, showed Ki value of 1.8 µM, as determined 
by displacement with tritiated [D-Ala2, N-Me-Phe4, 
Gly5-ol]-enkephalin ([3H]DAMGO) in rat cortex 
homogenates (see ESI for experimental details). The 
value was well above the Ki value for BChE inhibition, 
hence the competition, if any, would be insignificant. 
Compound 4 exhibited no significant inhibition of 
norepinephrine, dopamine or serotonin transporter 
proteins. Similarly, the BChE inhibitor showed no 
significant inhibition of cyclooxygenase, phospho-
diesterase, monoamine oxidase-A, or AChE. The latter 
is in agreement with previously conducted in vivo 
safety experiments in mice that showed that the 
sulfonamide is not an agonist on cholinergic 
receptors, because it did not produce any acute 
cholinergic adverse effects, even at 100 mg/kg [16]. 
On the other hand, the results showed inhibition 
values above cut-off limits, set at 50% inhibition, for 
muscarinic acetylcholine receptor (53.1%), adrenergic 
receptors α1A and α2A (71.7% and 60.9%, respectively) 
and for serotonin receptors (5-HT; a range from 84.3–
96.2%). Additional experiments conducted in our lab 
showed only 48% and 78% displacement of 
[3H]flunitrazepam and [3H]8-OH-DPAT, respectively, 
from GABAA and 5-HT1A receptors at 0.3 mM, a 
concentration substantially higher than the ones 
intended to use in PET imaging (see ESI for 
experimental details). It was therefore concluded that 
the radioactive analogue of 4, [11C]4, is an appropriate 
candidate for the use in in vivo determination of BChE 
abundance in the brain.  
 






Figure 7. Staining for BChE enzymatic activity in 4, 8 and 12-month-old brains of WT (A, C and F) and 5xFAD mice (B, D, E and G–I) using the Karnovsky-Roots method. BChE 
staining showed increase of enzyme activity in the hippocampus of 5xFAD at different ages in comparison to WT (A to F) mice. Magnified images show the correspondence of 




Biodistribution and metabolism studies of [11C]4 in 
WT mice showed favourable properties for in vivo PET 
imaging. Radiotracers used for PET studies need to 
fulfil certain requirements. Besides high affinity for 
the target, PET tracers need to show sufficient blood 
circulation, fast clearance from non-target organs, 
easy penetration into the target tissue and low 
metabolism [34]. In this work, in vivo PET studies 
were combined with ex vivo assays to assess 
biodistribution and metabolism of the newly 
developed PET tracer [11C]4. PET images showed 
rapid accumulation of radioactivity in the brain, with 
progressive decrease afterwards, demonstrating thus 
the capacity of [11C]4 to cross the BBB, as anticipated 
from logP values, and the relatively fast wash-out. In 
order to have an estimation of blood clearance, the 
concentration of radioactivity in blood was estimated 
by drawing a VOI in the heart. No specific uptake was 
observed in the myocardium, and hence a VOI could 
not be drawn in the left ventricle, typical approach to 
obtain image-derived input functions [35]. However, 
the delineation of a VOI in the heart provided 
valuable qualitative information that demonstrated a 
relatively fast blood clearance.  
Extraction of blood samples showed the 
presence of two major metabolites of [11C]4 at short 
times after administration. Noteworthy, these 
metabolites only partially accumulated in the brain 
(as derived from metabolite analysis in brain tissue) 
resulting in a higher fraction of parent compound in 
the brain when compared to that in the blood. 
Although not investigated in this study, the plasma 
metabolism analysis using LC-HRMS in previous 
work reports the detection of three possible 
metabolites: N-debenzylated, demethylated, and a 
demethylated + glucoronidated products [16]. Indeed, 





our radio-HPLC study revealed the presence of 
metabolites with higher polarities (tR = 2.0 and 3.4 
min), which is consistent with the proposed metabolic 
pathway in the above-mentioned study. The major 
radioactive peak (tR = 2 min) could therefore 
correspond to [11C]methanol, a side product of 
demethylated metabolite (compound 3, see Scheme 
1), and the minor radioactive peak (tR = 3.4 min) to 
[11C]N-debenzylated metabolic product. While 
[11C]N-debenzylated metabolite presented only 6% 
overall radioactivity in the brain at 15 min after 
injection, non-radioactive compound 3 exhibits 
10-fold lower inhibitory potency towards BChE than 
the parent compound (3, IC50 = 48.48 ± 7.48 nM, see 
ESI for more information). This, together with the 
relatively high molar activity of the radiotracer (which 
guarantees a very low molar concentration), suggests 
that the non-radioactive metabolite 3 shows negligible 
competition with [11C]4 for binding to BChE. 
Altogether, our results confirm that [11C]4 has 
favourable distribution and metabolism properties to 
assess BChE abundance in the brain using in vivo PET 
imaging. 
Blocking studies confirmed that [11C]4 specifically 
binds to the chosen target both ex vivo and in vivo. BChE 
blocking studies performed on brain tissue slices for 
both WT and AD animals using compound 4 and 
ethopropazine hydrochlorides as the blockers showed 
a decrease in the concentration of radioactivity in the 
presence of the blocker. Significant differences 
between AD and WT animals were found for 
ethopropazine at all investigated Bregma values 
(Figure S1), while in the case of 4, differences were 
only significant at Bregma = -2.8. Noteworthy, higher 
radioactivity concentration values were also observed 
for AD animals at Bregma = 1.2 and -5.8, with P values 
of 0.156 and 0.075. The lack of significant differences 
in these cases can be attributed to two reasons. First, 
images were acquired with a PET camera, due to the 
unavailability of an autoradiography system, severely 
limiting spatial resolution and sensitivity; and second, 
very low amount of radioactivity was used during the 
incubation, in order to maintain the concentration of 
[11C]4 below the Ki values. Still, differences could be 
observed, although the low values suggest that the 
density of BChE (Bmax) in the brain is low. 
Encouraged by the positive results, we tackled in 
vivo studies using the hydrochloride salt of the parent 
compound 4. Our results showed an initial increase of 
the radioactivity in the brain in both WT and AD 
animals, as demonstrated by PET imaging (Figures 2A 
and 2B). Although it seems surprising at first, the 
addition of a high concentration of hydrochloride salt 
of non-labelled compound 4 can displace [11C]4 
bound to BChE binding sites in tissues and blood, 
which results in an increase of the amount of free 
radiotracer in plasma and the consequent increase in 
total uptake of the radiotracer in the brain [36]. 
Noteworthy, [11C]4 was gradually washed out of the 
brain, resulting in lower abundance of the compound 
at the end of the imaging protocol in BChE-blocked 
animals compared to the control, non-BChE-blocked 
group for AD animals. Contrarily, similar levels of 
radiotracer uptake were achieved for WT animals in 
the presence and absence of the blocker (Figure 2B). 
These results, altogether, confirmed that [11C]4 
specifically binds to BChE and that the brain uptake of 
[11C]4 can be used as a surrogate for BChE abundance 
in vivo.  
Longitudinal PET studies show progressive 
accumulation of [11C]4 in 5xFAD mouse model for AD in 
the first 8 months. The average uptake of the 
radiotracer in different brain sub-regions suggested 
elevated BChE in the brain of the mouse model for 
AD compared to the WT littermates in an 
age-dependant manner. At the whole brain level, SUV 
mean values for AD animals obtained when analysing 
the last time frame of dynamic time-activity curves 
(ca. 50–60 min after tracer administration) exhibited 
an increment of 7.5% and 12.2% for 6 and 8 months 
with respect to 4 months. These values are consistent 
with ex vivo and in vivo blocking experiments, which 
showed values close to 10% and 20% decrease in 
uptake under blocking conditions, respectively. Of 
note, decrement of radioactive signal in the brains 
observed in the in vivo blocking studies is slightly 
larger than the increase of the signal uptake, observed 
in 5xFAD mice between 4 and 8 months of age. 
Although there are many possible reasons behind this 
discrepancy, including the differences in experimental 
set-up and spatial-resolution limitations of equipment 
(note that both experiments were carried out with 
different PET systems), off-target binding could be 
one possible reason for these differences. The reasons 
behind this phenomenon will be addressed in a new 
study in more details on larger animal models.  
Increased uptake, observed in different brain 
regions, including cerebral cortex, hippocampus, 
striatum, brain stem, cerebellum and thalamus, was in 
agreement with a previous work in which BChE 
presence was investigated in vivo using SPECT [18], 
and prevented the selection of an appropriate 
reference brain region, that would enable 
representation of the results as SUV relative to a 
common unaffected brain region.  






Figure 8. Deposition of Aβ in 12-month-old brains of WT (A and C) and 5xFAD mice (B, D, E, F). 4G8 antibody showed increase of Aβ plaque deposition in both the cortex 
(B) and hippocampus of 5xFAD (D) but not in WT mice (A and C). Magnified pictures of the cortex reveal a detailed distribution of Aβ plaques (B). Thioflavin S showed fibrillar 
amyloid accumulation in both the cortex (E) and hippocampus (F) of 5xFAD mouse. Scale bars, 0.5 mm. 
 
Following a steady increase of the uptake of 
[11C]4 in AD mice during the disease progression (4–8 
months of age; Figures 3 and 4) the uptake decreased 
at 10 and 12 months of age. Indeed, at 12 months of 
age SUV values for all investigated brain regions were 
lower than those measured at the age of 4 months, 
and slightly lower than those obtained for WT 
age-matched littermates. However, the presence of 
BChE in the different AD-brain regions could still be 
observed in ex vivo staining studies (vide infra). The 
reasons behind this unexpected phenomenon remain 
unclear. One explanation for the low brain uptake of 
[11C]4 in AD aged animals can be found in the binding 
mode of compound 4. As previously reported [16], 4 
interacts with Tyr332 side chain of human BChE via 
the positively charged nitrogen atom in the piperidine 
moiety, while the benzyl ring fits into the 
choline-binding pocket (groove contributed by Tyr82, 
Tyr332, Trp430, and Tyr440) and the naphthalene 
moiety interacts with Trp231 in the acyl-binding 
pocket via π-π interaction. Additionally, one of the 
sulfonamide oxygen atoms forms H-bond to the 
hydroxyl oxygen of Thr120. Binding of Aβ to the 
alleged “P-site – peripheral binding site” of BChE 
might limit the binding of compound 4 to BChE. 
Although the interaction of AChE and Aβ was 
demonstrated on several occasions [37, 38], for BChE 
the proof of binding is more elusive [39]. In this study 
high levels of mature β-amyloid plaques at advanced 
stages of the disease (IHC analysis) were found in 
brain regions that exhibited diminished uptake of 
[11C]4, while the drop in the uptake of [11C]4 was less 
severe in areas with low Aβ accumulation, i.e. the 
brain stem. Nevertheless, this is only a speculation 
and further experiments are needed to support this 
theory. Other factors, such as brain deterioration and 
decreased blood flow/perfusion, previously observed 
in a different mouse model of AD [40], could also 
contribute to this phenomenon.  
Longitudinal PET-[18F]florbetaben imaging is capable 
of in vivo detection of Aβ in 5xFAD animal model. The 
trend of increase of Aβ levels corresponds to BChE 





abundance from 4 to 8 months of age. This is the first 
study to evaluate longitudinal amyloid-PET evolution 
using [18F]florbetaben in 5xFAD AD model. Our 
results showed a significant increase of 
[18F]florbetaben uptake in the cortex and the 
hippocampus in months 5–11, which is consistent 
with Aβ deposition, previously reported for this 
animal model [41]. In addition, these results are in 
agreement with those described by Brendel and 
colleagues who showed a progressive [18F]florbetaben 
uptake increase from months 5 to 20 in different 
transgenic AD mouse models [42]. The increase in the 
presence of Aβ in the cortex and the hippocampus is 
in good agreement with the increased uptake of [11C]4 
in these regions. However, there was a mismatch in 
white matter-rich tissues, i.e. the brain stem and the 
cerebellum. While no Aβ plaques deposition was 
observed in the cerebellum (used as the reference 
region) and the brain stem of 5xFAD mice (Figure 5), 
BChE abundance followed the trend observed in 
other brain regions.  
Post mortem IHC results partially correlate with in 
vivo findings. Firstly, a substantial increase in BChE 
levels throughout the brain of 5xFAD, but not WT 
control, mice from 4 to 8 months of age was in a good 
agreement with PET imaging data. Contrarily to in 
vivo results, the ex vivo evaluation of 5xFAD mice 
brains showed a substantial accumulation and 
deposition of BChE at 12 months of age, while total 
and fibrillar Aβ in plaques were also increased in both 
the cortex and hippocampus of 5xFAD mice at the age 
12 months, corroborating the results observed with 
PET imaging. No difference in Aβ plaques deposition 
was observed in the cerebellum between AD and WT 
mice, confirming that this brain region is appropriate 
as reference region in this mouse model. Contrary to 
our expectations, ex vivo analysis showed minimal 
accumulation of BChE in the cerebellum of 5xFAD 
mice. This was surprising, especially because PET 
imaging and blocking studies confirmed the presence 
of BChE in this brain region. The observed increase in 
[11C]4 uptake in the white matter-rich areas, such as 
cerebellum, is expected if one considers that the 
increased demand for BChE is provoked by 
amyloid-associated damage. In fact, there is a large 
pool of evidence that suggest that BChE is present 
throughout the brain, mostly in subcortical layers and 
the white matter [43, 44]. Furthermore, the increase of 
BChE enzymatic activity in the brains of AD patients, 
especially in the white matter and glia cells, has 
previously been observed [45]. On the other hand, the 
result from ex vivo studies could be attributed to some 
compromises that needed to be made when analysing 
the stained tissue. Because all of the tissue sections 
were examined under the same conditions, to enable 
qualitative comparison between BChE deposition in 
different brain regions, high signal emanating from 
accumulated BChE around the plaques could 
overshadow the signal from dispersed BChE, 
rendering visualization of the enzyme in the 
cerebellum. Indeed, regional distribution of Aβ and 
BChE ex vivo revealed that Aβ deposited in areas with 
increased BChE abundance. This suggests coexistence 
of these two biomarkers and supports the theory that 
Aβ-driven conformational changes could lead to 
diminished binding capacity of [11C]4. Although 
further in-depth study of the effect of conformational 
changes of Aβ/BChE complexes on the binding 
affinity of 4 has not been conducted, the existence of 
such complexes has already been described in the 
literature [46, 47]. Considering these findings, 
significant drop in [11C]4 uptake at late stages of the 
disease in 5xFAD mice is not that surprising. Even 
more, substrates, used to assess BChE activity in the 
past [20] showed similar results.  
In conclusion, compound 4 is a potent inhibitor 
of BChE that, when appropriately radiolabelled, can 
be used for PET-imaging of AD progression in a 
mouse model for AD. Longitudinal PET imaging 
study on 5xFAD mice and its age-matched WT 
littermates, with the same genetic background, using 
carbon-11 radiolabelled [11C]4, revealed that the trend 
of longitudinal increase of BChE levels in the brain 
between AD and control mice correspond to Aβ 
deposition rate from 4 to 8 months of age. This was 
further confirmed by ex vivo BChE staining. 
Furthermore, this study reveals the importance of 
longitudinal evaluation of disease animal models and 
opens new insights into the disease progression from 
the perspective of BChE enzyme. It shows the 
importance of appropriate data evaluation and critical 
view of the results, especially when in vivo and ex vivo 
data does not match. This said, the use of larger 
animal models and human tissue is currently in 
progress to confirm our findings, to dig deeper into 
the mechanism of the disease, and to support the 
discovery of new diagnostic and therapeutic tools for 
AD. This study is a first step towards the use of BChE 
as a possible biomarker for the early or differential 
diagnosis of AD.  
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